Navidea Biopharmaceuticals Company Profile (NYSEMKT:NAVB)

About Navidea Biopharmaceuticals (NYSEMKT:NAVB)

Navidea Biopharmaceuticals logoNavidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. NAV5001 is an iodine-123 (I-123) radiolabeled single-photon emission computed tomography (SPECT) imaging agent being developed as an aid in the diagnosis of Parkinson's disease (PD) and other movement disorders, with potential use as a diagnostic aid in dementia. NAV4694 is a fluorine-18 (F-18) radiolabeled positron emission tomography (PET) imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer's disease (AD) and mild cognitive impairment (MCI).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Health Care Equipment
  • Symbol: NYSEMKT:NAVB
  • CUSIP: 63937X10
  • Web: www.navidea.com/
Capitalization:
  • Market Cap: $65.76 million
  • Outstanding Shares: 162,006,000
Average Prices:
  • 50 Day Moving Avg: $0.40
  • 200 Day Moving Avg: $0.49
  • 52 Week Range: $0.29 - $1.16
P/E:
  • Trailing P/E Ratio: 0.8325
  • Foreward P/E Ratio: -13.53
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $21.05 million
  • Price / Sales: 3.12
  • Book Value: $0.10 per share
  • Price / Book: 3.94
Profitability:
  • EBIDTA: ($3,320,000.00)
  • Net Margins: -515.33%
  • Return on Equity: -65.90%
  • Return on Assets: -42.98%
Misc:
  • Average Volume: 286,038 shs.
  • Short Ratio: 30.49
 

Frequently Asked Questions for Navidea Biopharmaceuticals (NYSEMKT:NAVB)

What is Navidea Biopharmaceuticals' stock symbol?

Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "NAVB."

How were Navidea Biopharmaceuticals' earnings last quarter?

Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) announced its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.02) EPS for the quarter. The firm had revenue of $0.61 million for the quarter. Navidea Biopharmaceuticals had a negative net margin of 515.33% and a negative return on equity of 65.90%. View Navidea Biopharmaceuticals' Earnings History.

Who are some of Navidea Biopharmaceuticals' key competitors?

Who are Navidea Biopharmaceuticals' key executives?

Navidea Biopharmaceuticals' management team includes the folowing people:

  • Eric K. Rowinsky M.D., Chairman of the Board
  • Michael M. Goldberg M.D., President, Chief Executive Officer, Director
  • Jed A Latkin, Chief Financial Officer, Interim Chief Operating Officer, Chief Accounting Officer
  • Frederick O. Cope Ph.D., Senior Vice President - Pharmaceutical Research and Clinical Development, Chief Scientific Officer
  • William J. Regan, Senior Vice President - Global Regulatory Affairs and Quality Chief Compliance Officer
  • Anthony S. Fiorino M.D. Ph.D., Director
  • Mark I. Greene M.D. Ph.D., Director
  • Michael Rice, Director

Who owns Navidea Biopharmaceuticals stock?

Navidea Biopharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.02%), Harel Insurance Investments & Financial Services Ltd. (0.48%), California Public Employees Retirement System (0.23%), Spark Investment Management LLC (0.22%), Virtu KCG Holdings LLC (0.21%) and Goldman Sachs Group Inc. (0.18%). Company insiders that own Navidea Biopharmaceuticals stock include Brent L Larson, Jed Latkin and William J Regan. View Institutional Ownership Trends for Navidea Biopharmaceuticals.

Who sold Navidea Biopharmaceuticals stock? Who is selling Navidea Biopharmaceuticals stock?

Navidea Biopharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, Goldman Sachs Group Inc. and Northern Trust Corp. View Insider Buying and Selling for Navidea Biopharmaceuticals.

Who bought Navidea Biopharmaceuticals stock? Who is buying Navidea Biopharmaceuticals stock?

Navidea Biopharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Virtu KCG Holdings LLC and Vanguard Group Inc.. Company insiders that have bought Navidea Biopharmaceuticals stock in the last two years include Jed Latkin and William J Regan. View Insider Buying and Selling for Navidea Biopharmaceuticals.

How do I buy Navidea Biopharmaceuticals stock?

Shares of Navidea Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Navidea Biopharmaceuticals' stock price today?

One share of Navidea Biopharmaceuticals stock can currently be purchased for approximately $0.41.


MarketBeat Community Rating for Navidea Biopharmaceuticals (NYSEMKT NAVB)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  81 (Vote Outperform)
Underperform Votes:  67 (Vote Underperform)
Total Votes:  148
MarketBeat's community ratings are surveys of what our community members think about Navidea Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Navidea Biopharmaceuticals (NYSEMKT:NAVB) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Earnings by Quarter for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Earnings History by Quarter for Navidea Biopharmaceuticals (NYSEMKT NAVB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.02)$0.61 millionViewListenView Earnings Details
3/29/2017Q4 2016($0.02)$3.36 millionViewN/AView Earnings Details
8/4/2016Q216($0.03)($0.04)$5.24 million$5.40 millionViewN/AView Earnings Details
5/17/2016Q1($0.03)($0.02)$4.63 million$4.70 millionViewListenView Earnings Details
3/23/2016Q415($0.04)($0.02)$3.70 million$4.00 millionViewListenView Earnings Details
11/4/2015Q315($0.04)($0.05)$2.40 million$3.98 millionViewListenView Earnings Details
7/30/2015Q215($0.04)($0.06)$2.18 million$2.90 millionViewListenView Earnings Details
5/12/2015Q115($0.03)($0.05)$3.30 million$2.10 millionViewListenView Earnings Details
3/5/2015($0.04)($0.05)$1.95 million$2.20 millionViewN/AView Earnings Details
3/5/2015($0.04)($0.05)$1.95 million$2.20 millionViewN/AView Earnings Details
3/5/2015Q414($0.05)($0.05)$2.10 million$2.20 millionViewListenView Earnings Details
11/6/2014Q314($0.06)($0.05)$1.54 million$2.30 millionViewListenView Earnings Details
8/6/2014Q214($0.07)($0.07)$1.05 million$1.05 millionViewListenView Earnings Details
5/7/2014Q114($0.10)($0.06)$0.90 million$0.75 millionViewListenView Earnings Details
3/6/2014Q413($0.08)($0.10)$0.74 million$0.54 millionViewListenView Earnings Details
11/6/2013Q313($0.08)$0.09$0.97 million$0.40 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.07)($0.09)$0.55 million$0.20 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.07)($0.06)$0.02 millionViewN/AView Earnings Details
3/6/2013Q4 2012($0.08)($0.08)ViewN/AView Earnings Details
11/8/2012Q312$0.21($0.09)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Current Year EPS Consensus Estimate: $-0.0800 EPS
Next Year EPS Consensus Estimate: $-0.0300 EPS

Dividends

Dividend History for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Insider Trades by Quarter for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Institutional Ownership by Quarter for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Insider Trades by Quarter for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/29/2017William J ReganSVPBuy20,000$0.53$10,600.00View SEC Filing  
5/30/2017Jed LatkinCFOBuy7,600$0.44$3,344.00View SEC Filing  
5/22/2017Jed LatkinCFOBuy25,359$0.45$11,411.55View SEC Filing  
12/1/2015Brent L LarsonCFOSell12,500$1.50$18,750.00View SEC Filing  
10/1/2015Brent L LarsonCFOSell12,500$2.27$28,375.00View SEC Filing  
9/1/2015Brent L LarsonCFOSell12,500$1.88$23,500.00View SEC Filing  
6/1/2015Brent L LarsonCFOSell12,500$1.24$15,500.00View SEC Filing  
5/29/2015Gordon A TroupDirectorBuy10,000$1.31$13,100.00View SEC Filing  
11/14/2014Michael M GoldbergDirectorBuy100,000$1.08$108,000.00View SEC Filing  
11/10/2014Brendan A FordDirectorBuy10,000$1.03$10,300.00View SEC Filing  
5/9/2014Mark Jerome PykettCEOBuy10,000$1.34$13,400.00View SEC Filing  
3/10/2014Brent LarsonCFOSell41,500$1.96$81,340.00View SEC Filing  
3/10/2014Frederick CopeSVPSell15,000$1.96$29,400.00View SEC Filing  
3/10/2014Mark Jerome PykettCEOSell120,000$1.96$235,200.00View SEC Filing  
11/8/2013Brendan FordDirectorBuy20,000$1.45$29,000.00View SEC Filing  
11/8/2013Brent LarsonCFOBuy5,000$1.39$6,950.00View SEC Filing  
11/8/2013Frederick CopeSVPBuy3,500$1.43$5,005.00View SEC Filing  
11/8/2013Mark Jerome PykettCEOBuy10,900$1.35$14,715.00View SEC Filing  
3/15/2013Gordon A TroupDirectorBuy7,000$2.70$18,900.00View SEC Filing  
3/15/2013Mark Jerome PykettCEOBuy1,850$2.70$4,995.00View SEC Filing  
3/15/2013Thomas H TulipEVPBuy17,500$2.82$49,350.00View SEC Filing  
3/15/2013William J ReganSVPBuy5,000$2.71$13,550.00View SEC Filing  
9/14/2012Thomas H TulipEVPBuy15,000$2.70$40,500.00View SEC Filing  
9/12/2012Brendan A FordDirectorBuy5,000$2.64$13,200.00View SEC Filing  
9/11/2012Mark Jerome PykettCEOBuy4,000$2.64$10,560.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Latest Headlines for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Source:
DateHeadline
finance.yahoo.com logoNavidea Biopharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 9 at 6:33 AM
finance.yahoo.com logoEdited Transcript of NAVB earnings conference call or presentation 9-Aug-17 12:00pm GMT
finance.yahoo.com - August 12 at 8:09 PM
americanbankingnews.com logoNavidea Biopharmaceuticals Inc (NYSEMKT:NAVB) Announces Earnings Results
www.americanbankingnews.com - August 10 at 2:36 PM
nasdaq.com logoACHN Soars On PNH Data, ACAD Abuzz, ALDR On Track, Zealand To Debut On Nasdaq - Nasdaq
www.nasdaq.com - August 9 at 3:37 PM
finance.yahoo.com logoInvestor Network: Navidea Biopharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - August 9 at 3:37 PM
finance.yahoo.com logoNavidea reports 2Q loss
finance.yahoo.com - August 9 at 3:37 PM
businesswire.com logoNavidea Biopharmaceuticals Reports Second Quarter 2017 ... - Business Wire (press release)
www.businesswire.com - August 9 at 2:30 AM
finance.yahoo.com logoNavidea Biopharmaceuticals Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 2:30 AM
finance.yahoo.com logoNavidea CEO to shareholders: 'With all due respect,' come up with a better idea for raising stock price
finance.yahoo.com - July 8 at 12:55 PM
finance.yahoo.com logoNavidea CEO: Splitting company could boost struggling stock
finance.yahoo.com - July 6 at 7:18 AM
finance.yahoo.com logoNavidea shareholders reject 20-for-1 reverse stock split, don't endorse director nominees
finance.yahoo.com - July 3 at 11:43 PM
americanbankingnews.com logoWilliam J. Regan Acquires 20,000 Shares of Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) Stock
www.americanbankingnews.com - July 3 at 7:28 PM
reuters.com logoBRIEF-Navidea says on June 26, co and FTI Consulting entered into settlement agreement
www.reuters.com - June 30 at 2:16 AM
reuters.com logoBRIEF-Navidea enters exclusive license, distribution agreement for India with Sayre Therapeutics
www.reuters.com - June 20 at 7:48 PM
finance.yahoo.com logoNavidea Enters Exclusive License and Distribution Agreement For India with Sayre Therapeutics
finance.yahoo.com - June 20 at 7:48 PM
prnewswire.com logoDaily Technical Summary Reports on Biotech Stocks -- Illumina, Navidea Biopharma, Grifols, and Intercept Pharma - PR Newswire (press release)
www.prnewswire.com - June 16 at 7:59 AM
businesswire.com logoNavidea's Commercial Partner, Norgine BV, Launches LYMPHOSEEK® in Europe - Business Wire (press release)
www.businesswire.com - June 13 at 11:55 PM
reuters.com logoBRIEF-Navidea says commercial partner Norgine launches lymphoseek in Europe
www.reuters.com - June 12 at 4:07 PM
finance.yahoo.com logoNavidea’s Commercial Partner, Norgine B.V., Launches LYMPHOSEEK® in Europe
finance.yahoo.com - June 12 at 4:07 PM
finance.yahoo.com logoNavidea getting new revenue source as cancer diagnostic aid launches in Europe
finance.yahoo.com - June 12 at 4:07 PM
finance.yahoo.com logoETFs with exposure to Navidea Biopharmaceuticals, Inc. : June 9, 2017
finance.yahoo.com - June 9 at 6:58 PM
finance.yahoo.com logoNavidea Biopharmaceuticals to Present at the 7th Annual LD Micro Invitational Investor Conference
finance.yahoo.com - June 1 at 7:34 PM
finance.yahoo.com logoETFs with exposure to Navidea Biopharmaceuticals, Inc. : May 30, 2017
finance.yahoo.com - May 30 at 6:27 PM
finance.yahoo.com logoNavidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017
finance.yahoo.com - May 26 at 7:38 PM
americanbankingnews.com logoNavidea Biopharmaceuticals Inc (NAVB) CFO Acquires $11,411.55 in Stock
www.americanbankingnews.com - May 23 at 8:35 PM
finance.yahoo.com logoNavidea pays former CEO $618,000 after losing arbitration over his firing
finance.yahoo.com - May 16 at 6:28 PM
reuters.com logoBRIEF-Navidea Biopharmaceuticals reports Q1 earnings $0.53/shr
www.reuters.com - May 12 at 12:15 AM
finance.yahoo.com logoEdited Transcript of NAVB earnings conference call or presentation 10-May-17 12:00pm GMT
finance.yahoo.com - May 10 at 11:51 PM
bizjournals.com logoNavidea proposes 20-1 reverse stock split to prop up sagging shares
www.bizjournals.com - May 9 at 6:23 PM
finance.yahoo.com logoNavidea Biopharmaceuticals Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 6:23 PM
bizjournals.com logoBiotech Stocks on Investors' Radar -- BioMarin Pharma, Eyegate Pharma, Navidea Biopharma, and Cellectar Biosciences
www.bizjournals.com - May 9 at 11:37 AM
americanbankingnews.com logoNavidea Biopharmaceuticals (NAVB) Receiving Somewhat Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - April 27 at 3:28 PM
finance.yahoo.com logoNavidea Biopharmaceuticals Invited to Present Data at Two Major Upcoming Conferences
finance.yahoo.com - April 25 at 6:01 PM
finance.yahoo.com logoETFs with exposure to Navidea Biopharmaceuticals, Inc. : April 19, 2017
finance.yahoo.com - April 19 at 6:48 PM
finance.yahoo.com logoNavidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q4, 2016 By the Numbers : April 4, 2017
finance.yahoo.com - April 7 at 11:26 AM
finance.yahoo.com logoETFs with exposure to Navidea Biopharmaceuticals, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 11:26 AM
reuters.com logoBRIEF-Navidea Q4 loss per share $0.02
www.reuters.com - March 29 at 7:25 PM
us.rd.yahoo.com logoNavidea Provides Corporate Update and Reports Full Year 2016 Results
us.rd.yahoo.com - March 29 at 7:25 PM
bizjournals.com logoNavidea halved losses in 2016, projects positive cash flow in 2017
www.bizjournals.com - March 29 at 7:25 PM
reuters.com logoBRIEF-Navidea Biopharmaceuticals files for non timely 10-K
www.reuters.com - March 17 at 12:31 AM
bizjournals.com logoWhy Navidea’s looking ahead to entrepreneurial life after deal
www.bizjournals.com - March 10 at 9:36 AM
biz.yahoo.com logoNAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Mat
biz.yahoo.com - March 9 at 8:29 AM
finance.yahoo.com logoNavidea Completes Sale of North American Rights of Lymphoseek® to Cardinal Health
finance.yahoo.com - March 3 at 6:44 PM
bizjournals.com logoNavidea closes Lymphoseek sale to Cardinal Health; lender CRG accepts loan payment, drops liens
www.bizjournals.com - March 3 at 6:44 PM
biz.yahoo.com logoNAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - March 2 at 6:58 PM
streetinsider.com logoNavidea Biopharma (NAVB) Reports CRG to Sell Stock of Macrophage Owned by Company - StreetInsider.com
www.streetinsider.com - February 24 at 4:09 PM
streetinsider.com logoUPDATE: Navidea Biopharma (NAVB) Reports Settlement ... - StreetInsider.com
www.streetinsider.com - February 23 at 11:51 PM
streetinsider.com logoUPDATE: Navidea Biopharma (NAVB) Reports Settlement Agreement with CRG Allowing Close of Cardinal Transaction
www.streetinsider.com - February 23 at 6:50 PM
reuters.com logoBRIEF-Navidea Biopharmaceuticals says reaches settlement with CRG relating to loan agreement
www.reuters.com - February 23 at 6:50 PM
biz.yahoo.com logoNAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Other Events
biz.yahoo.com - February 16 at 6:20 PM

Social

This page was last updated on 9/23/2017 by MarketBeat.com Staff